Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1. Nixon, C. E., Park, S., Pond-Tor, S., Raj, D., Lambert, L. E., Orr-Gonzalez, S., Barnafo, E. K., Rausch, K. M., Friedman, J. F., Fried, M., Duffy, P. E., & Kurtis, J. D. Clinical and Vaccine Immunology, 24(7):e00068–17, /cdli/24/7/e00068–17.atom, July, 2017. Number: 7
Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1 [link]Paper  doi  abstract   bibtex   
Naturally acquired antibodies to Plasmodium falciparum schizont egress antigen 1 (PfSEA-1A) are associated with protection against severe malaria in children. Vaccination of mice with SEA-1A from Plasmodium berghei (PbSEA-1A) decreases parasitemia and prolongs survival following P. berghei ANKA challenge. To enhance the immunogenicity of PfSEA-1A, we identified five linear B-cell epitopes using peptide microarrays probed with antisera from nonhuman primates vaccinated with recombinant PfSEA-1A (rPfSEA-1A). We evaluated the relationship between epitope-specific antibody levels and protection from parasitemia in a longitudinal treatment-reinfection cohort in western Kenya. Antibodies to three epitopes were associated with 16 to 17% decreased parasitemia over an 18-week high transmission season. We are currently designing immunogens to enhance antibody responses to these three epitopes.
@article{nixon_identification_2017,
	title = {Identification of {Protective} {B}-{Cell} {Epitopes} within the {Novel} {Malaria} {Vaccine} {Candidate} {Plasmodium} falciparum {Schizont} {Egress} {Antigen} 1},
	volume = {24},
	issn = {1556-6811, 1556-679X},
	url = {http://cvi.asm.org/lookup/doi/10.1128/CVI.00068-17},
	doi = {10.1128/CVI.00068-17},
	abstract = {Naturally acquired antibodies to Plasmodium falciparum schizont egress antigen 1 (PfSEA-1A) are associated with protection against severe malaria in children. Vaccination of mice with SEA-1A from Plasmodium berghei (PbSEA-1A) decreases parasitemia and prolongs survival following P. berghei ANKA challenge. To enhance the immunogenicity of PfSEA-1A, we identified five linear B-cell epitopes using peptide microarrays probed with antisera from nonhuman primates vaccinated with recombinant PfSEA-1A (rPfSEA-1A). We evaluated the relationship between epitope-specific antibody levels and protection from parasitemia in a longitudinal treatment-reinfection cohort in western Kenya. Antibodies to three epitopes were associated with 16 to 17\% decreased parasitemia over an 18-week high transmission season. We are currently designing immunogens to enhance antibody responses to these three epitopes.},
	language = {en},
	number = {7},
	urldate = {2019-11-28},
	journal = {Clinical and Vaccine Immunology},
	author = {Nixon, Christina E. and Park, Sangshin and Pond-Tor, Sunthorn and Raj, Dipak and Lambert, Lynn E. and Orr-Gonzalez, Sachy and Barnafo, Emma K. and Rausch, Kelly M. and Friedman, Jennifer F. and Fried, Michal and Duffy, Patrick E. and Kurtis, Jonathan D.},
	editor = {Wilkins, Patricia P.},
	month = jul,
	year = {2017},
	note = {Number: 7},
	keywords = {Accessories, Application - Antibody Validation / Epitope Mapping, Application - Infectious Diseases, Application - Vaccine Development, Country - USA, Other Organisms, PEPperCHIP - Customized - Linear, PEPperMAP - Epitope Mapping - Linear, Sample Type - Serum},
	pages = {e00068--17, /cdli/24/7/e00068--17.atom},
}

Downloads: 0